Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | WNT3A | P56704 | 7/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23525007 | 1.00 | NPC1 (0.62) | NPC1AAK1ALDH1A1KMT2AMAPK1 | |
| SCHEMBL6528205 | 0.75 | AAK1 (0.70) | NPC1AAK1ALDH1A1KMT2AMAPK1 | |
| SCHEMBL23524968 | 0.74 | ITK (0.42) | NPC1AAK1KMT2AMAPK1 | |
| SCHEMBL23524967 | 0.74 | ITK (0.42) | NPC1AAK1KMT2AMAPK1 | |
| SCHEMBL17493831 | 0.74 | AAK1 (1.00) | NPC1AAK1ALDH1A1KMT2AMAPK1 | |
| SCHEMBL16098443 | 0.70 | WNT3A (0.56) | ALDH1A1WNT3A | |
| SCHEMBL16097522 | 0.70 | WNT3A (0.56) | ALDH1A1WNT3A | |
| SCHEMBL23567966 | 0.70 | AAK1 (0.50) | NPC1AAK1ALDH1A1KMT2AKDM4E | |
| SCHEMBL6533994 | 0.69 | AAK1 (0.52) | NPC1AAK1ALDH1A1KMT2AMAPK1 | |
| SCHEMBL28847419 | 0.69 | CYP3A4 (0.35) | NPC1AAK1ALDH1A1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230280220-A1 | Benzimidazole Derivative Compounds and Uses Thereof | PFIZER INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-11661419-B2 | Benzimidazole derivative compounds and uses thereof | PFIZER INC. (US) | 2023-05-30 | — | — | US | disclosed |
| CN-115087655-A | Benzimidazole derivatives | 辉瑞公司 | 2022-09-20 | — | — | CN | disclosed |
| US-20210188829-A1 | Chemical Compounds | PFIZER INC. (US) | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11661419-B2 | Benzimidazole derivative compounds and uses thereof | ITK, HRH4, BLK | NPC1 1581/4885AAK1 521/4885ALDH1A1 242/4885 |
| US-20210188829-A1 | Chemical Compounds | ITK, HRH4, HRH1 | NPC1 1188/4885AAK1 402/4885ALDH1A1 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.